Evidence map›Paper›PMID 41975069›Full record

ArticleCell death and differentiation2026

Targeting CAFs-derived PCSK6 inhibits redistribution of PD-L1 and restores response of CD8

Qianming Du, Yuxiang Fei, Tao Li, Deju Wang, Sheng Hu, Ya Yang, Wenlian Tang, Xu Zhang, Hongting Diao, Chao Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qianming Du *General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, PR China. duqianming@njmu.edu.cn.ORCID http://orcid.org/0000-0002-1092-2899
Yuxiang Fei *School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, PR China.
Tao Li *General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, PR China.
Deju WangSchool of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, PR China.
Sheng HuCollege of Pharmacy, Xinjiang Medical University, Urumqi, PR China.
Ya YangCollege of Pharmacy, Xinjiang Medical University, Urumqi, PR China.
Wenlian TangJiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, PR China.
Xu ZhangDepartment of Pharmacy, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu University of TCM, Chengdu, PR China. xuzhang1989@cdutcm.edu.cn.
Hongting DiaoSchool of Nursing, Nanjing Medical University, Nanjing, PR China. dht@njmu.edu.cn.
Chao LiuSchool of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, PR China. liuchaogermany@126.com.ORCID http://orcid.org/0000-0002-8204-399X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81803763National Natural Science Foundation of China (National Science Foundation of China) 82172558National Natural Science Foundation of China (National Science Foundation of China) 82204394National Natural Science Foundation of China (National Science Foundation of China) 82273971National Natural Science Foundation of China (National Science Foundation of China) 82274163National Natural Science Foundation of China (National Science Foundation of China) 82303498National Natural Science Foundation of China (National Science Foundation of China) 82373112National Natural Science Foundation of China (National Science Foundation of China) 82574443
6 · The paper itself

Abstract

Carcinoma-associated fibroblasts (CAFs) are core components of the tumor microenvironment, which contribute to tumor initiation and progression through mediating immune suppression. In this study, eight activated CAF subpopulations were identified by single-cell sequencing (scRNA-seq). A specific subtype of CAFs, characterized by PCSK6 expression, strengthened PD-L1 membrane distribution, which contributed to the cytotoxic CD8

Identifiers

PMID41975069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.